Pfizer Global Medical Grants – 2022/2023 Global NASH ASPIRE RFP

Well-being, Health and Biomedical Discovery

Deadlines

Academic Unit: inquire with unit

Memorial Deadline: Thursday 13th, October 2022

External Deadline: Thursday 20th, October 2022


Description

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Date RFP Issued: September 1, 2022
Geographic Scope: Global
Clinical Area: Nonalcoholic steatohepatitis (NASH)
Link to full RFP: 2022/2023 Global NASH ASPIRE
LOI due date: October 20, 2022
[Please note the deadline is 23:59 Eastern Time (New York, GMT -5).]
Full Proposal Deadline: *March 2023
*Only accepted LOIs will be invited to submit full proposals
[Please note the deadline is 23:59 Eastern Time (New York, GMT -5).]


Specific Area of Interest: 
The ASPIRE NASH program will evaluate submitted research proposals that cover areas in basic, clinical and translational sciences. The research proposals with innovative and the potential of high impact in advancing the learning about NASH will be encouraged.

The followings are the main areas of priority with high unmet needs:

  • – Biopsy-confirmed NASH prevalence, clinical outcomes, and healthcare utilization
  • – Innovations in the use of non-invasive tools in the care of patients with NASH
    – Understanding genetic drivers of NASH and identification of fast progressors

Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Jessica Romano, Grant Officer (jessica.romano@pfizer.com).


Funding Sources

Pfizer Inc



This opportunity was posted by: RGCS

Last modified: September 1, 2022